Venthera is a young and dynamic company within the BridgeBio family. Our lead program is focused on the delivery of PI3Ka inhibitors for the treatment of venous and lymphatic malformations involving the cutaneous tissue. Our “right drug, right tissue” approach to product design is built upon a foundation of targeting drugs to the proximal node of known pathways with validated genetic mutations, integrated with a quantitative assessment of how best to deliver an effective amount of the drug to affected target.
Who You Are
We are seeking a translational scientist to support the discovery and development of kinase inhibitors for the treatment of rare, monogenic, dermatological conditions.
The translational scientist will work with leading academic scientists and clinicians, as well as contract research organizations to design and execute supportive in vitro and in vivo pharmacology, PK/PD assessment, biomarker development, and lead the development of clinical target engagement assays and companion diagnostics. This position reports to the CEO and works with all functional areas.
You will also leverage this expertise and the knowledge generated at Venthera as we apply the “right drug, right tissue” approach to other monogenic dermal diseases with high unmet need. This involves aiding in the evaluation of new opportunities to treat such diseases and leading the translational biology that will ultimately be an instrumental part of growing and advancing a broad portfolio of life-changing therapies.
- In vitro pharmacological profiling of lead and backup candidates
- Establish and utilize animal models to demonstrate in vivo activity, PK/PD profiling
- Integrate with vitro, in vivo, and human pathology information to develop quantitative models forecasting effective dosing ranges for early human testing
- Lead the development of biomarkers and target engagement assays to support clinical trials
- Assess the viability of potential expansion indications for the dermal application of PI3K inhibitors
- Evaluate and develop project concepts for the treatment of other monogenic dermatological diseases
- Writing primary pharmacology sections of regulatory submissions
Education, Experience & Skills Requirements
- Ph.D., MD/Ph.D. or equivalent experience in pharmacology, disease modeling, or related discipline
- 10 years of industry experience in early-stage translational medicine
- Deep understanding of major oncogenes and related pathways
- Ability to work in a small company, largely virtual environment
- Highly self-motivated
- Ability to manage complexity and uncertainty
- Strong team interaction and communication skills
- Embraces the Venthera core values: putting the patient at the center of every decision; focus on rigorous science; have a speed of action and decision making; be radically transparent.
- Bonus: Bioanalytical/DMPK experience
What we offer
- Patient Days, where we are fortunate enough to learn more about the lives we are looking to impact and a real exchange of ideas as to how we can improve our efforts
- A culture inspired by our values: put patients first; think independently, be radically transparent; act nimbly, and let the science speak
- Learning and development training to help employees be the best version of themselves
- Collaborative business environment
- Excellent compensation package (Base, Performance Bonus, Stock, RSU programs)
- Excellent benefits package
- Flexible PTO
- With office locations in San Francisco, Boston, New York, and Raleigh, there are ample cross-collaboration opportunities with other BridgeBio Pharma programs
- A fast-paced, data-driven, work environment with world-class R&D minds and capabilities
- Work with the most productive groups of R&D operators in the industry
- Partnerships with leading institutions
- A platform for meaningful scientific contributions to shine
- Commitment to Diversity & Inclusion – with initiatives like Women at Bridge, we are committed to fostering an inclusive environment where every person feels respected for who they are, empowered to contribute, inspired to lead, and supported in their efforts to do so